American Urological Association (AUA) Accepts Androxal(R) Versus Topical Gel Comparative Study for Podium Presentation at Annual

American Urological Association (AUA) Accepts Androxal(R) Versus Topical Gel
Comparative Study for Podium Presentation at Annual Meeting

  *Abstract Title: Evaluation of Enclomiphene (Androxal®) and Testim® on
    Testosterone (T), Pituitary Hormones and Sperm Function
  *Presenters: Dr. John Dean (Past President International Society of Sexual
    Medicine), Dr. Andrew McCullough (Urological Institute of North Eastern
    NY)
  *Key Conclusions: The study shows that Androxal may provide effective
    therapy in men with secondary hypogonadism, particularly in those wishing
    to preserve reproductive status; clinically significant suppression of
    spermatogenesis in topical testosterone group

THE WOODLANDS, Texas, March 25, 2013 (GLOBE NEWSWIRE) -- Repros Therapeutics
Inc.^® (Nasdaq:RPRX) today announced that the American Urological Association
(AUA) has accepted key data on Androxal for presentation at the annual meeting
in San Diego, CA, May 4-8^th, 2013. The data presented are from a
double-blind, placebo and active control study of two doses of Androxal (12.5
and 25mg) with open label on demand Testim gel in 120 patients with secondary
hypogonadism over a 3 month period.

Androxal acts at the level of the pituitary as a selective estrogen receptor
modulator (SERM) to block the negative feedback of estrogen on the pituitary
hormones (LH and FSH). Restoration of LH (secondary hypogonadal males having
low levels) should provide rapid and effective normalization of T levels
without excursion into the supra normal range. In addition, preservation of
FSH levels in Androxal treated patients should ensure that there is no
negative impact on sperm function. Overall, this study shows that Androxal may
provide effective therapy in men with secondary hypogonadism, particularly in
those wishing to preserve fertility.

Andrew McCullough, MD, Professor of Urology/Division of Surgery, Albany
Medical College noted, "For decades the treatment of hypogonadism has been
limited to testosterone replacement. Acceptance of this data as a podium
presentation into a special "late breaking" session is important and may
represent the beginning of a paradigm shift in the primary treatment of
hypogonadism. As in diabetes, where replacement of insulin is second line to
oral hypoglycemic agents, perhaps stimulation of endogenous testosterone
production should represent the first line treatment of hypogonadism, not only
in the infertile man but also with late onset hypogonadism. The importance of
the diagnosis and treatment of hypogonadism is increasingly recognized by the
urologic and endocrine societies. The importance of the correct treatment of
hypogonadism is evidenced by the plenary session at the AUA entitled Critical
Discussion: Exogenous Testosterone, A Preventable Cause of Male Infertility."

About Repros Therapeutics Inc.^®

Repros Therapeutics focuses on the development of small molecule drugs for
major unmet medical needs that treat male and female reproductive disorders.

Any statements made by the Company that are not historical facts contained in
this release are forward-looking statements that involve risks and
uncertainties, including the ability to raise additional needed capital on a
timely basis in order for it to continue to fund development of its Androxal^®
and Proellex^® programs, have success in the clinical development of its
technologies, the reliability of interim results to predict final study
outcomes, and such other risks which are identified in the Company's most
recent Annual Report on Form 10-K and in any subsequent quarterly reports on
Form 10-Q. These documents are available on request from Repros Therapeutics
or at www.sec.gov. Repros disclaims any intention or obligation to update or
revise any forward-looking statements, whether as a result of new information,
future events or otherwise.

For more information, please visit the Company's website at
http://www.reprosrx.com.

The Repros Therapeutics Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=7738

CONTACT: Repros Therapeutics Inc.
         Joseph Podolski (281) 719-3447
         President and Chief Executive Officer
        
         Investor Relations:
         Thomas Hoffmann
         The Trout Group
         (646) 378-2931

company logo
 
Press spacebar to pause and continue. Press esc to stop.